{"id":"NCT03785340","sponsor":"Ocugen","briefTitle":"Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)","officialTitle":"A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients With Dry Eye Disease (DED)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-03","primaryCompletion":"2019-02-25","completion":"2019-02-25","firstPosted":"2018-12-24","resultsPosted":"2022-06-06","lastUpdate":"2022-07-18"},"enrollment":252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"Brimonidine Tartrate","otherNames":["OCU-310"]},{"type":"DRUG","name":"Placebos","otherNames":["Ophthalmic buffered saline solution"]}],"arms":[{"label":"OCU-310","type":"EXPERIMENTAL"},{"label":"Placebos","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the treatment of Dry Eye Disease (DED). Half of participants will receive Brimonidine and half will receive ophthalmic buffered saline (placebo).","primaryOutcome":{"measure":"Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score","timeFrame":"Baseline, 4 weeks (Day 28)","effectByArm":[{"arm":"OCU-310","deltaMin":73,"sd":13.6},{"arm":"Placebo","deltaMin":72.7,"sd":12.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.739"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":126},"commonTop":[]}}